SUN Pharmaceutical Industries Limited — Ramipril Exporter Profile
Indian Pharmaceutical Exporter · #7 for Ramipril · $4.8M export value · DGFT Verified
SUN Pharmaceutical Industries Limited is the #7 Indian exporter of Ramipril with $4.8M in export value and 361 verified shipments. SUN Pharmaceutical Industries Limited holds a 5.3% market share in Ramipril exports across 5 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.
SUN Pharmaceutical Industries Limited — Ramipril Export Profile: Buyers & Destinations
Where Does SUN Pharmaceutical Industries Limited Export Ramipril?
| Country | Value | Shipments | Share |
|---|---|---|---|
| CANADA | $1.8M | 136 | 40.5% |
| BELGIUM | $1.5M | 149 | 34.5% |
| AUSTRALIA | $1.1M | 80 | 24.8% |
| UKRAINE | $7.2K | 4 | 0.2% |
| ROMANIA | $12 | 1 | 0.0% |
SUN Pharmaceutical Industries Limited exports Ramipril to 5 countries. The largest destination is CANADA accounting for 40.5% of SUN Pharmaceutical Industries Limited's Ramipril shipments, followed by BELGIUM (34.5%) and AUSTRALIA (24.8%). These destinations reflect SUN Pharmaceutical Industries Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ramipril from SUN Pharmaceutical Industries Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $1.4M | 143 |
| SUN PHARMA CANADA INC | CANADA | $897.0K | 49 |
| SUN PHARMA ANZ PTY LTD. | AUSTRALIA | $483.2K | 37 |
| SUN PHARMA ANZ PTY LTD | AUSTRALIA | $311.4K | 22 |
| SUN PHARMA CANADA INC., | CANADA | $229.4K | 25 |
| SUN PHARMA CANADA LNC | CANADA | $221.8K | 21 |
| SUN PHARMA ANZ PTY LIMITED | AUSTRALIA | $202.9K | 15 |
| M S SUN PHARMA CANADA INC | CANADA | $172.5K | 8 |
| M/S. SUN PHARMA CANADA INC | CANADA | $139.6K | 18 |
| YUSEN LOGISTICS BENELUX | BELGIUM | $80.5K | 3 |
SUN Pharmaceutical Industries Limited supplies Ramipril to 21 buyers globally. The largest buyer is YUSEN LOGISTICS BENELUX BELGIUM (BELGIUM), followed by SUN PHARMA CANADA INC (CANADA) and SUN PHARMA ANZ PTY LTD. (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ramipril Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?
India exported $82.5M worth of Ramipril through 4,977 shipments from 177 suppliers to 93 countries, serving 389 buyers globally. SUN Pharmaceutical Industries Limited contributes $4.8M to this total, accounting for 5.3% of India's Ramipril exports. SUN Pharmaceutical Industries Limited ships Ramipril to 5 countries through 21 buyers.
What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Ramipril Exports?
SUN Pharmaceutical Industries Limited's average Ramipril shipment value is $13.2K per consignment, based on 361 shipments totaling $4.8M. The largest destination is CANADA (40.5% of SUN Pharmaceutical Industries Limited's Ramipril exports).
How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Ramipril Exporters?
SUN Pharmaceutical Industries Limited ranks #7 among 177 Indian Ramipril exporters with a 5.3% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($16.0M), GENO PHARMACEUTICALS PRIVATE LIMITED ($14.0M), AUROBINDO PHARMA LTD ($13.3M). SUN Pharmaceutical Industries Limited processed 361 shipments to 5 destination countries.
What Ramipril Formulations Does SUN Pharmaceutical Industries Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| RAMIPRIL AND HYDROCHLOROTHIAZIDE TABLETS | $378.7K | 15 |
| RAMIPRIL TABLETS 5MG ( RAMIPRIL STADA TA | $167.1K | 5 |
| APO-RAMIPRIL TAB 5 MG EACH TABLET CONTAI | $137.9K | 5 |
| APO-RAMIPRIL TAB 2.5 MG EACH TABLET CONTAINS: RAMIPRIL BP 2.5 MG EXCIPIENTS QS.PACK : Box3x10s | $92.4K | 7 |
| RAMIPRIL AND HYDROCHLOROTHIAZIDE TABLETS5+12.5MG (TARO RAMIPRIL+HCTZ TAB 5+12.5MG)EACH TABLETCONTIANS**NOS | $73.8K | 6 |
| RAMIPRIL TABLETS 10MG ( RAMIPRIL STADA T | $62.4K | 4 |
| RAMIPRIL AND HYDROCHLOROTHIAZIDE TABLETS10 12 5MG TARO RAMIPRIL HCTZ RXY TAB 10 12 5MG PACK 100s Bottl Batch PTD5 | $53.6K | 2 |
| RAMIPRIL AND HYDROCHLOROTHIAZIDE TABLETS10+12.5MG (TARO-RAMIPRIL+HCTZ RXY TAB 10+12.5MG) EACH TABLET CONTAINS: **** | $53.3K | 3 |
| RAMIPRIL TABLETS 10MG RAMIPRIL STADA TAB 10MG EACH TABLET CONTAINS: RAMIPRILPH.EUR 10MG PACK : 4x7s | $50.0K | 1 |
| RAMIPRIL AND HYDROCHLOROTHIAZIDE TABLETS5+25MG ( RAMIPRIL HCTZ SUN TAB 5+25MG )EACH TABLET CONTAINS:RAMIPRIL PH.EUR 5M | $50.0K | 1 |
SUN Pharmaceutical Industries Limited exports 222 distinct Ramipril formulations including tablets, capsules, syrups, and combination drugs. The top formulation is RAMIPRIL AND HYDROCHLOROTHIAZIDE TABLETS with 15 shipments worth $378.7K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Ramipril to Key Markets
What SUN Pharmaceutical Industries Limited must comply with to export Ramipril to its top destination countries
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does SUN Pharmaceutical Industries Limited Compare to Nearest Ramipril Exporters?
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | IND SWIFT LIMITED | $6.4M | 307 | 3 | $20.8K |
| 6 | ZENTIVA PRIVATE LIMITED | $4.9M | 233 | 5 | $21.0K |
| 7 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ★ | $4.8M | 361 | 5 | $13.2K |
| 4 | SANOFI INDIA LIMITED | $4.5M | 90 | 12 | $50.0K |
| 8 | MICRO LABS LIMITED | $4.2M | 141 | 2 | $30.1K |
SUN Pharmaceutical Industries Limited ranks #7 among 177 Indian Ramipril exporters. Average shipment value of $13.2K compared to the market average of $466.2K. The closest competitors by value are IND SWIFT LIMITED and ZENTIVA PRIVATE LIMITED.
Which Indian Ports Ship Ramipril Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 658 | 13.2% |
| JNPT/ NHAVA SHEVA SEA | 553 | 11.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 305 | 6.1% |
| SAHAR AIR | 291 | 5.8% |
| JNPT | 271 | 5.4% |
| DELHI AIR CARGO ACC (INDEL4) | 214 | 4.3% |
| DELHI AIR | 201 | 4.0% |
| VIZAG SEA | 194 | 3.9% |
Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Ramipril Exports
Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)
In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)
The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)
SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)
Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.
About SUN Pharmaceutical Industries Limited
SUN Pharmaceutical Industries Limited exports 118 products worth $979.8M. Beyond Ramipril, top products include Strip, Esomeprazole, Magnesium, Calcium, Omeprazole. View the complete SUN Pharmaceutical Industries Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ramipril — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ramipril shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 370 individual customs records matching SUN Pharmaceutical Industries Limited exporting Ramipril, covering 222 formulations to 5 countries via 21 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 93+ countries, 389+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ramipril Export Data from SUN Pharmaceutical Industries Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for SUN Pharmaceutical Industries Limited's Ramipril exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SUN Pharmaceutical Industries Limited
Full Company Profile →
118 products · $979.8M total trade · 25 categories
Ramipril Stats
Company Overview
Top Products by SUN Pharmaceutical Industries Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for SUN Pharmaceutical Industries Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ramipril. For current shipment-level data, contact TransData Nexus.